Precision Medicine in Veterinary Science: Veterinary Clinics of North America

Revolutionizing Veterinary Oncology: Precision Medicine Paves the Way for Personalized Cancer Treatment in Dogs

PALO ALTO, Calif. (January 17, 2024)

Researchers at FidoCure by One Health Company the One Health Company, which has pioneered a new approach to treating canine cancer using AI and genomics, have published an article with Vidium Animal Health detailing significant advancements in veterinary oncology, mirroring the successes seen in human cancer care through precision medicine.

The study, published last week in the peer-reviewed journal Veterinary Clinics of North America, reports major advances in human cancer care due to personalized drugs that are matched to the molecular profile of patients' tumors. These findings have led to an increased integration of precision medicine in veterinary oncology and detail how this new approach to treating pet dogs with cancer is already saving the lives of dogs and their human companions.

Key Highlights:

1. Advanced Diagnostic Tools for Canine Cancer: Genomic platforms like FidoCure provide veterinarians with  access to advanced lab tests that provide deep insights into the specific gene mutations that are driving a patient’s cancer.
2. Targeted Therapies for Canine Patients: The identification of specific gene mutations in canine tumors has enabled the use of targeted therapies that were originally developed for human cancer for canine cancer patients. This approach offers new, personalized treatment avenues in veterinary medicine.
3. Improving Treatment Outcomes: The success rate for matching dogs with effective precision therapies is expected to improve as more evidence accumulates. This marks a significant advancement and a new era in veterinary medicine, moving away from the one-track treatment method.
4. Optimizing Care with Precision Testing: Precision testing in veterinary oncology is varied, with each test serving specific purposes in cancer management - diagnosis, prognosis, and therapy. The selection and timing of these tests are customized to meet the unique needs of each canine patient, rather than following a standardized treatment method. Fidocure is designed to include all cancer types and can therefore offer a personalized treatment regimen for any canine cancer patient.
5. Moving Towards a New Standard in Veterinary Oncology: An expanding database linking canine genetic mutations to effective drugs is enhancing veterinarians' ability to interpret genomic results. This development is paving the way for standardized, genetically guided treatment in veterinary oncology.

“The newfound results not only highlight the significant advancement in veterinary medicine but also underscore the deep connection between human and animal health,” said One Health Chief Medical Officer, Dr. Gerald Post. “As we continue to explore the world of precision medicine, the implications for advancements offer hope and new possibilities in the fight against cancer on both ends of the leash”

The results of these advancements follow the April 2023 study published in Nature Precision Oncology, conducted by Stanford AI Health and One Health, which detailed how researchers used artificial intelligence to analyze how specific combinations of genetic mutations associated with cancer and targeted therapy affected the outcomes of 2,119 canine patients. with cancer from more than 200 veterinary clinics.

###

ABOUT FIDOCURE

FidoCure is the first to bring the latest advances in human oncology - individualized, precision medicine - to dogs with cancer. We are a mission driven company that delivers the most sophisticated diagnostics and creates a personalized treatment plan for each dog. Our flagship product, FidoCure® Next Generation DNA Sequencing Test, leverages technologies and therapies approved for human use, with additional data specific to canine cancer. With FidoCure, dogs with cancer receive access to the latest scientific advances in cancer care, from tests to treatment. FidoCure is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Learn more at www.fidocure.com.

FidoCure is the first to bring the latest advances in human oncology - individualized, precision medicine - to dogs with cancer. We are a mission driven company that delivers the most sophisticated diagnostics and creates a tailored treatment plan for each dog. Our flagship product, FidoCure® Next Generation DNA Sequencing Test, leverages technologies and therapies approved for human use, with additional data specific to canine cancer. With FidoCure, dogs with cancer receive access to the latest scientific advances in cancer care, from tests to treatment. FidoCure is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Learn more at www.fidocure.com.

For media inquiries, please contact:

HAUS for FidoCure@hausb.io